Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Elizabeth J Phillips; Chonlaphat Sukasem; Michelle Whirl-Carrillo; Daniel J Müller; Henry M Dunnenberger; Wasun Chantratita; Barry Goldspiel; Yuan-Tsong Chen; Bruce C Carleton; Alfred L George Jr; Taisei Mushiroda; Teri Klein; Roseann S Gammal; Munir Pirmohamed

doi:10.1002/cpt.1004

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Clin Pharmacol Ther. 2018 Apr;103(4):574-581. doi: 10.1002/cpt.1004. Epub 2018 Feb 2.

Authors

Elizabeth J Phillips¹, Chonlaphat Sukasem^{2

3}, Michelle Whirl-Carrillo⁴, Daniel J Müller^{5

6}, Henry M Dunnenberger⁷, Wasun Chantratita^{8

9}, Barry Goldspiel¹⁰, Yuan-Tsong Chen^{11

12}, Bruce C Carleton¹³, Alfred L George Jr¹⁴, Taisei Mushiroda¹⁵, Teri Klein⁴, Roseann S Gammal^{16

17}, Munir Pirmohamed¹⁸

Affiliations

¹ Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
³ Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand.
⁴ Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
⁵ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
⁶ Department of Psychiatry and Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
⁷ Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
⁸ Virology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
⁹ Center for Medical Genomics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
¹⁰ Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
¹¹ Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
¹² Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
¹³ Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, and BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
¹⁴ Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
¹⁵ Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Science, Yokohama, Japan.
¹⁶ Department of Pharmacy Practice, MCPHS University, Boston, Massachusetts, USA.
¹⁷ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁸ Department of Pharmacology, University of Liverpool, Liverpool, UK.

Abstract

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

Publication types

Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anticonvulsants / pharmacology
Carbamazepine / pharmacology*
Drug-Related Side Effects and Adverse Reactions* / genetics
Drug-Related Side Effects and Adverse Reactions* / prevention & control
HLA-B Antigens / genetics*
Humans
Oxcarbazepine / pharmacology*
Pharmacogenetics / methods
Pharmacogenetics / standards

Substances

Anticonvulsants
HLA-B Antigens
Carbamazepine
Oxcarbazepine

Abstract

Publication types

MeSH terms

Substances

Grants and funding